You are here

Polymers for Infection Resistant Urinary Catheters

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DK065319-01
Agency Tracking Number: DK065319
Amount: $99,995.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
CCL BIOMEDICAL, INC. BOX 276
NEWARK, DE 19715
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 NINA LAMBA
 (410) 939-9356
 cclbiomed@verizon.net
Business Contact
 NINA LA
Phone: (302) 831-2213
Email: CCLBIOMED@COMCAST.NET
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant):
Hospital acquired infections are on the increase and compromise the quality and cost-effectiveness of health care. A significant number of device-associated infections occur with urinary catheters. New and effective strategies to supplement and complement traditional infection control practices are urgently needed. Ideally, new technologies should display broad spectrum activity against bacteria, viruses, fungi, etc. but should not encourage the emergence of antibiotic resistant bacterial strains. In this program we propose to develop new silver biocides to prevent urinary catheter-related infections. These antimicrobial agents will be covalently bound to a polymer matrix, to provide polymers with sustained antibacterial activity. The physical properties of the polymers will be measured. Evaluation of the antimicrobial effects of the active polymers will be performed using gram positive and gram negative bacteria. In Phase II we will conduct more comprehensive laboratory and in vivo testing, and develop the biocides to be highly effective yet economically competitive. It is envisaged that developing new infection resistant materials with broad applicability will reduce the incidence of device-related infections, the associated costs of treatment, and patient mortality. The potential savings in healthcare cost savings could run into billions of dollars.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government